25 W Watkins Mill Rd,
About Arcellx Inc.
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. Arcellx’s vision is to bring ARC-SparX platform cell therapies to millions of patients who can self-administer prescribed SparX proteins under the care of academic and community practices.
6 articles with Arcellx Inc.
Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting
100% (12/12) of patients with relapsed and refractory multiple myeloma treated with Arcellx’s BCMA-specific CAR-modified T-cell therapy achieved responses per IMWG criteria
Arcellx to Present Data from Phase 1 Study of CART-ddBCMA Demonstrating Continued Positive Response in Patients with Relapsed and Refractory Multiple Myeloma at the 2021 ASCO Annual Meeting
Arcellx, a privately held clinical-stage biopharmaceutical company, announced the release of updated clinical data from the first 12 evaluable patients treated in the ongoing Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed and refractory multiple myeloma.
Arcellx Announces Executive Appointments Dr. Christopher Heery joins as Chief Medical Officer and Neeraj Teotia joins as Chief Commercial Officer
Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs and Neeraj Teotia has been named Chief Commercial Officer where he will have responsibility for marketing, sales, and health economics
Arcellx, based in Gaithersburg, Maryland, closed on a Series C financing round worth $115 million.
Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies
Arcellx, a privately held clinical-stage biopharmaceutical company, announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies.
Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma. ACLX-001 is the first clinical application of the company’s ARC-SparX platform of controllable and adaptable cell therapies.